Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus

Clinical Transplantation

Volumn 31, Issue 5, 2017, Pages

  Morales, Amilcar L ^a   Liriano Ward, Luz ^b   Tierney, Amber ^c   Sang, Michelle ^a   Lalos, Alexander ^a   Hassan, Mohamed ^c   Nair, Vinay ^b   Schiano, Thomas ^b   Satoskar, Rohit ^a   Smith, Coleman ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

chronic hepatitis C; HIV; kidney transplant; ledipasvir sofosbuvir

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; ERYTHROPOIETIN; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; TACROLIMUS; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; HEADACHE; HEMODIALYSIS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY DONOR; KIDNEY GRAFT; LEUKOPENIA; MALE; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; VIRUS LOAD; ANALOGS AND DERIVATIVES; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; GENETICS; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEPACIVIRUS; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; FEMALE; FLUORENES; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; URIDINE MONOPHOSPHATE;

EID: 85016299780     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12941     Document Type: Article

References (42)

1. Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant. 2014;14:2206-2220.
2. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2:563-575.
3. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol. 2004;56:249-257.
4. Saab S, Martin P, Brezina M, Gitnick G, Yee HF. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308-315.
5. Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-1299.
6. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-2342.
7. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.
8. Sezer S, Ozdemir FN, Akcay A, Arat Z, Boyacioglu S, Haberal M. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant. 2004;18:619-623.
9. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation. 1996;61:886-889.
10. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-1160.
11. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant. 2002;17:129-133.
12. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21:314-324.
13. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation. 2000;70:255-261.
14. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374-1381.
15. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49:613-624.
16. Huskey J, Wiseman AC. Chronic viral hepatitis in kidney transplantation. Nat Rev Nephrol. 2011;7:156-165.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
18. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
19. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc. 1994;26:2075.
20. Ozgür O, Boyacioğlu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant. 1995;10:2104-2106.
21. Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22:24-33.
22. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382.
23. Fontana RJ, Brown RS, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22:446-458.
24. Crittenden NE, Buchanan LA, Pinkston CM, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation. Liver Transpl. 2016;22:635-643.
25. Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.
26. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.
27. Colombo M, Aghemo A, Liu H, et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. International Liver Congress. European Association for the Study of the Liver. Barcelona, Spain, 2016.
28. Coilly A, Samuel D. Pros and Cons: usage of organs from donors infected with hepatitis C virus - revision in the direct-acting antiviral era. J Hepatol. 2016;64:226-231.
29. Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000;14(4 Pt 2):391-396.
30. Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192-1196.
31. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation. 2007;83:853-857.
32. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:1452-1461.
33. Cruzado JM, Carrera M, Torras J, Grinyó JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant. 2001;1:171-178.
34. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004;43:131-139.
35. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238-1246.
36. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150-154.
37. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
38. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med. 2006;166:1632-1641.
39. Perez G, Ortiz-Interian C, Lee H, et al. Human immunodeficiency virus and human T-cell leukemia virus type I in patients undergoing maintenance hemodialysis in Miami. Am J Kidney Dis. 1989;14:39-43.
40. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705-713.
41. Campos-Varela I, Moreno A, Morbey A, et al. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy. Aliment Pharmacol Ther. 2016;43:1319-1329.
42. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org2016 Accessed October 15, 2016